Literature DB >> 11229821

Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases.

H Asakura1, Y Ontachi, T Mizutani, M Kato, M Saito, E Morishita, M Yamazaki, Y Suga, A Takami, K Miyamoto, S Nakao.   

Abstract

Tissue factor pathway inhibitor (TFPI) is primarily synthesized by vascular endothelial cells and is found in vivo in association with endothelial cells, lipoproteins, or in free form. Free TFPI is the most potent and important type, because it is released from endothelial cells following an injection of heparin, or as a result of pathological stimuli. In order to study the role of TFPI in disease, the concentration of free form TFPI was measured in the plasma of 114 patients suffering from disseminated intravascular coagulation (DIC), as the result of several underlying diseases. Plasma antigen levels of free TFPI were significantly higher even in those patients not exhibiting DIC than in normal healthy subjects. These levels were even higher among patients exhibiting DIC, especially those with acute promyelocytic leukemia or cancer, receiving continuous heparin drip infusions. A significant correlation was observed between the plasma antigen levels of free form TFPI and those of fibrin/fibrinogen degradation products, and free form TFPI and plasmin inhibitor complex (r = 0.428, P < 0.0001 and r = 0.329, P < 0.0001, respectively) among 114 DIC patients. There were no significant differences between the plasma levels of free TFPI in DIC patients with or without multiple organ failure. It has been suggested that the plasma levels of free TFPI are closely related to the levels of fibrinolysis occurring in DIC patients, although further study is required to clarify the degree to which TFPI is expressed by endothelial cells during DIC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229821     DOI: 10.1097/00001721-200101000-00001

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  Successful Administration of Recombinant Human Soluble Thrombomodulin α (Recomodulin) for Disseminated Intravascular Coagulation during Induction Chemotherapy in an Elderly Patient with Acute Monoblastic Leukemia Involving the t(9;11)(p22;q23) MLL/AF9 Translocation.

Authors:  Kazutaka Takagi; Toshiki Tasaki; Takahiro Yamauchi; Hiromichi Iwasaki; Takanori Ueda
Journal:  Case Rep Hematol       Date:  2011-08-02

2.  Tissue factor and tissue factor pathway inhibitor in chronically inflamed gallbladder mucosa.

Authors:  Jacek Liczko; Tomasz Stawski; Małgorzata Zaba; Józef Kurek; Daniel Sabat; Grzegorz Wyrobiec; Dorota Domal-Kwiatkowska; Damian Dudek; Marek Kucharzewski; Krzysztof Helewski
Journal:  Biomed Res Int       Date:  2014-02-27       Impact factor: 3.411

Review 3.  Expression of tissue factor pathway inhibitor by endothelial cells and platelets.

Authors:  Susan A Maroney; Alan E Mast
Journal:  Transfus Apher Sci       Date:  2008-02-07       Impact factor: 1.764

Review 4.  Antiphospholipid antibodies: paradigm in transition.

Authors:  Lawrence L Horstman; Wenche Jy; Carlos J Bidot; Yeon S Ahn; Roger E Kelley; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; Seyed Ali Mousavi; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2009-01-20       Impact factor: 8.322

5.  Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.

Authors:  Chrysoula Papageorgiou; Georges Jourdi; Eusebe Adjambri; Amanda Walborn; Priya Patel; Jawed Fareed; Ismail Elalamy; Debra Hoppensteadt; Grigoris T Gerotziafas
Journal:  Clin Appl Thromb Hemost       Date:  2018-10-08       Impact factor: 2.389

6.  Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue-specific fibrin deposition.

Authors:  S A Maroney; B C Cooley; R Sood; H Weiler; A E Mast
Journal:  J Thromb Haemost       Date:  2007-10-25       Impact factor: 5.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.